Skip to main content

Bringing new medicines to patients with unmet medical need is built on collaborations between healthcare professionals and the pharmaceutical industry.

To improve health outcome the industry is dependent on the invaluable work done by practitioners to improve both care and treatment options. A healthy transparent working relationship between the industry and healthcare professionals/organizations relys on transparency when it comes to disclosure of payments made to healthcare professionals.

Immedica will on this page publish disclose payments for attendance, sponsorships, speaker fees and other consultancy fees. In some countries the authority’s has local databases where it is mandatory to disclose the above and Immedica will follow local regulations.

Their may be calender years where no interactions have taken place, which why the list of disclosures may not be complete for every calender year.

Methodological Note for Patient Organisations and the Public including Patients and Journalists Disclosure and Disclosure
2025 Neurocrine UK Limited - Methodological Note for HCP/ORDM/HCO disclosure
2025 Neurocrine UK Limited - HCP & HCO disclosures
2025 Payments/support to patient organisations, UK
2025 Disclosure tracker, UK
2025 Disclosure methodology, UK
2025 Disclosure for pos and the public, UK
2025 Patient and Public methodology for disclosure, UK
2025 Patient and Public statement global website, UK

2024 Patient organisation statement for Immedica global website, UK
2024  Patient and public statement for Immedica global website, UK
2024 Patient patient and public methodology, UK
2024 Patient organisation methodology, UK
2024 ImmedicaPharmaUK method, UK
2024 Immedica code mandatory disclosure, UK
2024 Diurnal PAG Methodological note
2024 Diurnal method
2024 Diurnal Template
 
2023 Diurnal Disclosure Report (updated)
2023 Diurnal Methodology
2023 Patient Group Disclosures

 

 2022 Diurnal Disclosure Report
2022 Diurnal methodology
2022 Diurnal Patient Organisation Disclosure